Grenoble (France), January 17th, 2018
PX’Therapeutics, a CDMO (Contract Development and Manufacturing Organization) has signed an agreement with Advaxis, Inc., a US-based, clinical stage biotechnology company, to support it in the process development of cancer immunotherapies based on Advaxis’ proprietary, attenuated Listeria monocytogenes (Lm) platform.
PX’Therapeutics will support Advaxis in taking its drug discovery cycle to the next level, optimizing process development and further discovery of the impact of bacterial culture parameters on product quality. This will ultimately result in the development of a robust industrial production process.
“Partnering with PX’Therapeutics will help catapult our Lm-Technology production process and advance our mission to put our technologies in the hands of patients who desperately need them,” said Michael Grace, Vice President of Technical Operations at Advaxis.
Claire Untereiner, COO of PX’Therapeutics commented: “We are really excited about this new collaboration! PX’Therapeutics looks forward to bringing its expertise to the development of this important project.”
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot mutation therapy and prostate cancer.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, which is available at www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
PX’Therapeutics is a Contract Development and Manufacturing Organization (CDMO) specializing in the development of biologics (proteins including antibodies and antibody fragments, cells, and micro-organisms), for research and clinical applications. With more than 1,000 projects implemented since its creation in 2000, PX’Therapeutics is recognized for its scientific expertise coupled with state-of-the-art GMP capacities, in addition to team flexibility and committed dedication to the success of customers’ projects. Today, the company’s mission is to accelerate the development of biologics thanks to a combination of services, from lead optimization and process development through to GMP manufacturing and CMC consulting.
More information on www.px-therapeutics.com
Directrice des Opérations
7 parvis Louis Néel – CS20050 BHT52A
38040 Grenoble Cedex – FRANCE
Tél: +33 (0)4.38.02.36.50